AZD 8529

Drug Profile

AZD 8529

Alternative Names: AZD-8529

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Glutamate modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 17 Mar 2015 National Institute on Drug Abuse plans a phase II trial for Smoking withdrawal in USA (NCT02401022)
  • 03 May 2011 AstraZeneca completes its phase 0 trial in healthy volunteers in the US [completion after discontinuation] (NCT00985933)
  • 09 Mar 2011 AstraZeneca completes enrolment in its phase 0 trial in healthy volunteers in the US (NCT00985933)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top